Proteomics Targeting Dualsystems Biotech provides custom proteomics focused on ligand-receptor capture (LRC-TriCEPS) to identify membrane targets and off-targets on living cells, with capability to profile ligands such as proteins, peptides, viruses, and increasingly small molecules using the latest TriCEPS version. Flow-TriCEPS enables pre-optimization of binding conditions before the main identification study, shortening project timelines. This makes them a strong partner for pharma and biotech teams needing target deconvolution, mechanism studies, or off-target risk assessment in early to mid-stage discovery.

Industry Collaborations Existing collaboration with aTyr Pharma in 2022 demonstrates credibility and a track record of industry partnerships, suggesting an openness to co-development and milestone-driven engagements. As a compact Swiss provider, they can offer flexible, cost-efficient engagement models for drug discovery programs that require niche proteomics services without large CRO commitments.

EU Growth Potential Located in Zurich, they sit in a strategic European biotech ecosystem with access to academia and industry partners across Switzerland and the EU, offering a gateway for collaborations, sponsored research, and joint grant opportunities. Their specialized membrane-target identification capabilities align with current trends in precision proteomics, enabling opportunities for funded projects and long-term partnerships.

Advanced Targeting Capabilities Advanced target discovery capabilities, including identification of small molecule targets with an updated TriCEPS platform, position them for safety and lead-optimization workflows where off-target information is critical. They can offer targeted deconvolution services or integration into existing discovery pipelines as a flexible, outcome-driven service.

Lean Service Model With a lean team and a focused service model, Dualsystems Biotech can scale through pilot projects, CRO partnerships, or white-label collaborations, appealing to early-stage biotech startups and larger pharma/biotech customers seeking nimble proteomics support without fixed overhead. This agility enables rapid onboarding and tailored pricing structures to win initial work and expand as programs grow.